



# Bioteknologisk FoU – store muligheter for både børs og katedral

Stig W. Omholt

NTNU Biotechnology: the Confluence of Life Sciences,  
Mathematical Sciences and Engineering



# PASTEUR'S QUADRANT

*Basic Science  
and Technological  
Innovation*


*Donald E. Stokes*

Quest for fundamental understanding



Basic  
research  
(Niels Bohr)

Use-inspired  
basic research  
(Louis Pasteur)




Applied  
research  
(Thomas Edison)



Consideration for use





“store muligheter for børs og katedral”

# Bioteknologi - definisjon

Anvendelse av naturvitenskap og teknologi på levende organismer og på deler, produkter og modeller av disse, slik at levende eller ikke-levende materialer endres for å frembringe kunnskap, varer og tjenester.



biology is technology

ROBERT H. CARLSON



**“Biology is the  
oldest  
technology.”**

## ▸ NTNU Biotechnology

[NTNU Biotechnology](#)[Research & Development](#)[Core facilities](#)[Studies](#)[Sabbatical at NTNU?](#)[Job openings](#)

## Research and Development

All R&D activities sorting under the NTNU Biotechnology umbrella stay firmly within the confines of the OECD definition of biotechnology:


*"the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services"*

Our R&D streams - emerging from the confluence of life sciences, mathematical sciences and engineering - define the core of the NTNU Biotechnology Programme. [Check them out...](#)

ENABLING TECHNOLOGY PROGRAMME 2013-2020

## NTNU Biotechnology - the Confluence of Life Sciences, Mathematical Sciences and Engineering

This is the main portal keeping you informed about biotechnology R&D at NTNU, the people involved, and available opportunities to contribute to this vibrant field as a student, PhD, postdoctoral, sabbatical or tenured fellow.



NTNU Biotechnology is one of the three enabling technology programmes at the Norwegian University of Science and Technology. Together they define the strategic core of NTNU's long-term R&D commitment within natural science and technology. The design of NTNU Biotechnology programme reflects the conviction that extensive transdisciplinary interaction between the life sciences, mathematical sciences and engineering is the key to transformative 21st century biotechnology. It is developed in close conjunction with [SINTEF](#), the largest independent research organisation in Scandinavia, and [St. Olavs hospital](#) (Trondheim University Hospital), which is tightly integrated with our [Faculty of Medicine and Health Sciences](#).

NTNU is the leading institution of the [Norwegian Centre for Digital Life](#) funded by the Research Council of Norway under its BIOTEK2021 programme. The centre's main mission is to become the major vehicle for reorienting and concerting Norwegian R&D on biotechnology in the years to come.

### Contact



Stig W. Omholt

Director/Research professor

Phone: +47 90 94 09 85

Email: [stig.omholt@ntnu.no](mailto:stig.omholt@ntnu.no)



Laila Berg

Coordinator, PhD

Phone: +47 73 41 21 09

Email: [laila.berg@ntnu.no](mailto:laila.berg@ntnu.no)



# NTNU Biotechnology

## The Confluence of Life Sciences, Mathematical Sciences and Engineering



### NTNU Human Physiome

The concerted global efforts towards making integrated mathematical descriptions of human physiology. [Read more.](#)



### NTNU Phenomics Technology

We have a long and successful tradition for blending engineering and biology for developing new measurement technology. [Read more.](#)



### NTNU Tissue Engineering

By merging advanced engineering with molecular and cellular biology we aim to make significant contributions to this technology. [Read more.](#)




### NTNU Genome Editing

We are in the process of taking advantage of the current revolution in making targeted genome sequence changes. [Read more.](#)



### NTNU Therapeutic Targeting

In most fields of medicine where therapeutic interventions involve application of drugs there is still tremendous potential for improvement. [Read more.](#)



### NTNU Analysis, Design and Control of Microbial Systems

Improved methodology for engineering microbes to perform specific tasks is key to industrial biotechnology. [Read more.](#)



### NTNU Biopolymer Engineering

We have a proven track record in tailoring biopolymers into new biomaterials for numerous

application areas within medicine and industry. [Read more.](#)



### NTNU Aquaculture Biotechnology

Maintaining a profitable and expansive aquaculture industry leaving minimal human footprints is a pressing issue. [Read more.](#)



### NTNU Synthetic Biology Engineering

Methodology for engineering new complex function in cells is a prerequisite for novel industrial biotechnology. [Read more.](#)



### NTNU Bioreactor Design and Operation

We aim to contribute to more efficient engineering of devices that support biologically active environments. [Read more.](#)



### NTNU Morphogenetic Engineering

Novel engineering concepts exploiting nature's capacity for self-organization has numerous applications. [Read more.](#)



### NTNU Responsible Research and Innovation

Developing methodology and mechanisms for anticipating and assessing the societal implications of our R&D activities. [Read more.](#)





## NTNU Biotechnology

### Research & Development

NTNU Analysis, Design and Control  
of Microbial Systems

NTNU Aquaculture Biotechnology

NTNU Bioreactor Design and  
Operation

NTNU Biopolymer Engineering

NTNU Genome Editing

NTNU Human Physiome

NTNU Morphogenetic Engineering

NTNU Phenomics Technology

NTNU Tissue Engineering

**NTNU Synthetic Biology  
Engineering**

NTNU Therapeutic Targeting

NTNU Responsible Research and  
Innovation

Core facilities


Studies

Sabbatical at NTNU?

Job openings

# NTNU Synthetic Biology Engineering

Engineering new complex functions in cells is a prerequisite for novel industrial biotechnology.


[About](#)
[Governance](#)
[Publications](#)
[Tag cloud](#)
[Network](#)
[People](#)
[Projects](#)

NTNU SYNTHETIC BIOLOGY ENGINEERING

## Synthetic Biology Engineering Steering Group



[Eivind Almaas](#)



[Trygve Brautaset](#)



[Martin H-Marriot](#)



[Rahmi Lale](#)



[Håvard Sletta](#)



[Finn Drabløs](#)



## NTNU Biotechnology

### Research & Development

[NTNU Analysis, Design and Control of Microbial Systems](#)

[NTNU Aquaculture Biotechnology](#)

[NTNU Bioreactor Design and Operation](#)

[NTNU Biopolymer Engineering](#)

[NTNU Genome Editing](#)

[NTNU Human Physiome](#)

[NTNU Morphogenetic Engineering](#)

[NTNU Phenomics Technology](#)

[NTNU Tissue Engineering](#)

### NTNU Synthetic Biology Engineering

[NTNU Therapeutic Targeting](#)

[NTNU Responsible Research and Innovation](#)

[Core facilities](#)


[Studies](#)

[Sabbatical at NTNU?](#)

[Job openings](#)

## NTNU Synthetic Biology Engineering

Engineering new complex functions in cells is a prerequisite for novel industrial biotechnology.



[About](#) [Governance](#) [Publications](#) [Tag cloud](#) [Network](#) [People](#) [Projects](#)



Result **10** of **668**

Publications	Authors	Journal	Year
<a href="#">No cancer predisposition or increased spontaneous mutation frequencies in NEIL DNA glycosylases-deficient mice</a>	Veslemøy Rolseth , Luisa Luna , Ann Karin Olsen , Rajikala Suganthan , Katja Scheffler , Christine G. Neurauter , Ying Esbensen , Anna Kuśnierczyk , Gunn A. Hildrestrand , Anne Graupner <a href="#">...more authors</a>	Scientific Reports	2017
<a href="#">Human chitotriosidase: Catalytic domain or carbohydrate binding module, who's leading HCHT's biological function</a>	Oscar Crasson , Gaston Courtade , Raphaël R. Léonard , Finn Lillelund Aachmann , François Legrand , Raffaella Parente , Denis Baurain , Moreno Galleni , Morten Sørli , Marylène Vandevenne	Scientific Reports	2017
<a href="#">Dynamic responses to silicon in Thalassiosira pseudonana - Identification, characterisation and classification of signature genes and their corresponding protein motifs</a>	Tore Brembu , Matilde Skogen Chauton , Per Winge , Atle M. Bones , Olav Vadstein	Scientific Reports	2017
<a href="#">The effects of phosphorus limitation on carbon metabolism in diatoms</a>	Tore Brembu , Alice Mühlroth , Leila Alipanah , Atle M. Bones	Philosophical Transactions of the Royal Society B: Biological Sciences	2017

## NTNU Biotechnology

### Research & Development

- NTNU Analysis, Design and Control of Microbial Systems
- NTNU Aquaculture Biotechnology
- NTNU Bioreactor Design and Operation
- NTNU Biopolymer Engineering
- NTNU Genome Editing
- NTNU Human Physiome
- NTNU Morphogenetic Engineering
- NTNU Phenomics Technology
- NTNU Tissue Engineering
- NTNU Synthetic Biology Engineering**
- NTNU Therapeutic Targeting
- NTNU Responsible Research and Innovation

### Core facilities


### Studies

### Sabbatical at NTNU?

### Job openings

# NTNU Synthetic Biology Engineering

Engineering new complex functions in cells is a prerequisite for novel industrial biotechnology.



- [About](#)
- [Governance](#)
- [Publications](#)
- [Tag cloud](#)
- [Network](#)
- [People](#)
- [Projects](#)

## Network




## Key metrics

**668**  
Publications


## Publications for 2017

**357**  
Institutions

**1360**  
Persons



## Co-authors grouped by country







## Transformative Research

## Introduction to Transformative Research

*Transformative research involves ideas, discoveries, or tools that radically change our understanding of an important existing scientific or engineering concept or educational practice or leads to the creation of a new paradigm or field of science, engineering, or education. Such research challenges current understanding or provides pathways to new frontiers.*

The purpose of this site is to provide a brief introduction to potentially transformative research and its support at NSF.

Email  Print  Share 




↑ Top



Facts do not cease to exist because they are ignored.  
Aldous Huxley



# Er den rektangulære livskurven oppnåelig?



# What is frailty?



**Definition:** a biologic syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems, and causing vulnerability to adverse outcomes.



# Fysiologi

**Studiet av funksjoner og aktiviteter til levende materiale (slik som organer, vev og celler) og tilhørende fysiske og kjemiske fenomener**

*Webster's Third New International Dictionary*

# IUPS Physiome: Molecular pathways to organ systems

Environment

Organism

Organ system

Organ

Heart




Lungs



Diaphragm





Knee



Colon



Liver




↑ x 1million


↓ 20 generations




Cardiac sheets




Acinus




Osteon




Lymph node



Liver lobule




Nephron









Tissue

Cell



Network  
Protein  
Gene  
Atom





# The heart physiome




torso





heart

tissue




cellular processes



cell-cell  
connections


## 3D cell




proteins



**amino acid  
sequence**



**genomic  
sequence**






**m**  
**=10<sup>9</sup>nm**

nm

# Signaling

1. cAMP signalling
2. Calcium signalling - via  
cADP-ribose signalling  
NAADP signalling  
Voltage operated channels (VOCs)  
Receptor operated channels (ROCs)  
IP<sub>3</sub>-Ca<sup>2+</sup> signalling (via PLC-PIP<sub>2</sub>)  
DAG-PKC signalling (via PLC-PIP<sub>2</sub>)  
PI 4-5P<sub>2</sub> signalling  
Inositol polyphosphate signalling  
PI 3-Kinase signalling
3. NO-cGMP signalling
4. Redox signalling
5. MAP-Kinase signalling
6. NF-κB signalling
7. Phospholipase D (PLD) signalling
8. Sphingomyelin signalling
9. JAK-STAT signalling
10. Smad signalling
11. Wnt signalling
12. Hedgehog signalling
13. Notch signalling
14. ER stress signalling
15. AMP signalling





# Infrastructure for linking Molecular Biology to Physiome

Physiome  
FieldML  
library

Cell type

Cell function

Cell process

CellML  
& SBML  
libraries

Molecular  
Biology

Model components  
annotated with  
ontologies

Structure & physics  
Tissue motifs

Meiosis

Sensing

Mitosis

Apoptosis

Growth

Motility

Contraction

Signalling

Transport

Adhesion

ECM protein  
synthesis

Cell cycle

Intracell. signalling

Calcium transport

Protein trafficking

Protein degradation

Electro-physiology

Cellular metabolism

Protein synthesis

Protein regulation

Gene regulation

Gene transcription

Cell  
receptors

Signalling  
modules

Ion  
channels

Metabolic  
modules

Gene  
networks

...

Genes  
miRNA  
mRNA

...

Proteins  
Sequence  
Structure  
PTMs  
Binding  
motifs

...

Lipids

...

Carbo-  
hydrates

...

# Scale Imaging Multi-scale Modelling

Organism

Organ system

Organ

Tissue


Cell

Network

Protein

Gene

Atom



Partial differential equations (PDEs)

Reaction-diffusion  $\frac{\partial C}{\partial t} + \mathbf{u} \cdot \nabla C = -\nabla \cdot (-k \nabla C) + f_s$

Fluid flow  $\frac{\partial \mathbf{u}}{\partial t} + \mathbf{u} \cdot \nabla \mathbf{u} = -\frac{1}{\rho} \nabla p + \nu \nabla^2 \mathbf{u}$

Finite elasticity  $\tau^{ij} |_{,i} = f^j$   $\tau^{ij} = f(e_{ij})$

$e_{ij} = \frac{1}{2} \left( \frac{\partial u_i}{\partial x_j} + \frac{\partial u_j}{\partial x_i} + \frac{\partial u_k}{\partial x_i} \frac{\partial u_k}{\partial x_j} \right)$

Electro-magnetic  $\nabla \cdot \mathbf{E} = \frac{\rho}{\epsilon}$   $\nabla \times \mathbf{E} = -\frac{\partial \mathbf{B}}{\partial t}$   
 $\nabla \cdot \mathbf{B} = 0$   $\nabla \times \mathbf{B} = \mu \mathbf{J} + \epsilon \frac{\partial \mathbf{E}}{\partial t}$

Differential algebraic equations

Bayesian network description

Molecular dynamics/coarse graining

Poisson-Boltzmann ...





#### Pleiotropy

The ability of a single genetic change to affect more than one phenotype.

\*Department of Biological Science, Florida State University, Tallahassee, Florida 32306-4295, USA.

†Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115, USA.

‡Centre for Integrative Genetics (CIGENE), Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, N-1432 Ås, Norway.

§Centre for Ecological and Evolutionary Synthesis, University of Oslo, NO-0316 Oslo, Norway.  
e-mails: [dhoule@bio.fsu.edu](mailto:dhoule@bio.fsu.edu);  
[dgovindaraju@partners.org](mailto:dgovindaraju@partners.org);  
[stig.omholt@umb.no](mailto:stig.omholt@umb.no)  
doi:10.1038/nrg2897

# Phenomics: the next challenge

David Houle\*, Diddahally R. Govindaraju† and Stig Omholt§||

**Abstract** | A key goal of biology is to understand phenotypic characteristics, such as health, disease and evolutionary fitness. Phenotypic variation is produced through a complex web of interactions between genotype and environment, and such a 'genotype–phenotype' map is inaccessible without the detailed phenotypic data that allow these interactions to be studied. Despite this need, our ability to characterize phenomes — the full set of phenotypes of an individual — lags behind our ability to characterize genomes. Phenomics should be recognized and pursued as an independent discipline to enable the development and adoption of high-throughput and high-dimensional phenotyping.

When the debate over whether to fund a human genome project flowered in the late 1980s, one of the scientific arguments offered in opposition was that only a small part of the genome was really worth knowing — the 3–5% that was then estimated to lie in and close to protein-coding regions<sup>1,2</sup>. The alternative approach to a genome project was molecular genetics as usual: first identify a region of the genome that is of functional interest, then target it for sequencing. Calls to continue this traditional model for dealing with genotyping were rapidly swept aside, and the Human Genome Project was realized in a few years.

Over the past 15 years, many authors have proposed that phenomics — large-scale phenotyping — is the natural complement to genome sequencing as a route to rapid advances in biology<sup>3–8</sup>. The response to these propositions has mostly been silence, implying that 'phenotyping as usual' — measuring a limited set of phenotypes that seem the most relevant — is adequate. We disagree and argue that the case for phenomics is as compelling now as the case for genomics was 25 years ago and indeed shares many similarities with that case.

Phenomic-level data are necessary to understand which genomic variants affect phenotypes, to understand pleiotropy and to furnish the raw data that are needed to decipher the causes of complex phenomena, including health, crop yields, disease and evolutionary fitness. Our limited ability to understand many important biological phenomena suggests that we are not already measuring all important variables and that broadening the possibilities will pay rich dividends. Fundamentally, we can choose between focusing our efforts on what we already think is important or deciding that much of what we do not yet measure will prove useful and interesting. The question 'why not measure it

all?' was fortunately affirmatively answered for genomes; it is now time to ask the same question for phenotypes.

The time is ripe to consider the value of phenomic-level efforts for several reasons. First, technologies for high-throughput phenotyping are becoming increasingly available. Second, conceptual, analytical and bioinformatics approaches that enable the use of very high-dimensional data are advancing rapidly. Third, dynamic models that link phenomena across levels — from genes to cells, to organs and through to the whole organism — are in reach. Finally, in most cases, phenotypic data continue to be the most powerful predictors of important biological outcomes, such as fitness, disease and mortality. Although analyses of genomic data have been successful at uncovering biological phenomena, they are — in most cases — supplementing rather than supplanting phenotypic information.


In this Review, we identify the scientific rationales for carrying out phenomics research and outline current approaches to obtaining phenomic data. We then describe some of the conceptual challenges to taking full advantage of phenomic-level data. Finally, we consider how to establish phenomics as an independent discipline.

## What is phenomics?

The current usage of the word 'phenome' to refer to the phenotype as a whole is due to the evolutionary biologist Michael Soulé<sup>9</sup>. We now define phenomics as the acquisition of high-dimensional phenotypic data on an organism-wide scale. Although phenomics is defined in analogy to genomics, the analogy is misleading in one respect. We can come close to completely characterizing a genome but not a phenome, because the information content of phenomes dwarves those of genomes:



Unknown  
Cardiovascular  
state



Known state



measure-  
ments

on  
patient

measure-  
ments

on  
model

error

Cardiovascular  
model

$$\dot{\mathbf{X}} = f(\mathbf{x}, \mathbf{u}, \alpha, t)$$

Adjust  $\alpha$  (parameters)  
for minimum error





The Virtual Physiological Human will revolutionise the way health knowledge is produced, stored and managed as well as the way in which healthcare is currently delivered.

European Commission







# Putting the James Black approach on steroids by use of multiscale physiological modelling

$$\begin{Bmatrix} \alpha_{11} \\ \alpha_{12} \\ \dots \\ \alpha_{1n} \end{Bmatrix} = \overline{\alpha}_1 \rightarrow M_1 \rightarrow \overline{P}_1 = \begin{Bmatrix} P_{11} \\ P_{12} \\ \dots \\ P_{1m} \end{Bmatrix}$$



Multidimensional sensitivity analysis ( $S(\overline{\alpha}_1, \overline{P}_1)$ )



Identify putative drug targets ( $\alpha_{1j}, \alpha_{1k}$ )



Construct lower-level model  $M_2$

$$\begin{Bmatrix} \alpha_{21} \\ \alpha_{22} \\ \dots \\ \alpha_{2z} \end{Bmatrix} = \overline{\alpha}_2 \rightarrow M_2 \rightarrow \overline{P}_1 = \begin{Bmatrix} P_{21} = \alpha_{1j} \\ P_{22} = \alpha_{1k} \\ \dots \\ P_{2v} \end{Bmatrix}$$



Multidimensional sensitivity analysis ( $S(\overline{\alpha}_2, \overline{P}_2)$ )




Identify putative drug targets ( $\alpha_{2i}, \alpha_{2l}$ )



.....



Drug design targeting parameters ( $\alpha_{ji}, \alpha_{jl}$ )



Drug targeting becomes a merge between multiscale physiological modelling + nonlinear control engineering + deep phenotyping